Sanofi recalls all lots of Allerject (0.15 mg/0.15 mL and 0.3 mg/0.3 mL strengths of epinephrine auto-injectors)

Sanofi-aventis Canada Inc., in consultation with Health Canada, is recalling all lots of Allerject (0.15 mg/0.15mL and 0.3 mg/0.3 mL strength epinephrine auto-injectors) from the Canadian market. A similar recall is taking place in the United States, where it’s sold as Auvi-Q. This recall is due to issues that may potentially affect the delivery of the required amount of the drug, epinephrine. Allerject is used as an emergency treatment by patients who are at risk and/or have a history of serious allergic reactions (anaphylaxis). In light of the need to manage supply associated with this recall, we are asking customers and pharmacists to limit the replacement of Allerject to one unit or the appropriate number of units as instructed by your healthcare professional until full alternative stock is available.

Contact your pharmacy to arrange returning your Allerject device and to obtain a replacement epinephrine auto-injector with the same dose. Consult your pharmacist to ensure you understand how to properly use the replacement auto-injector. In the event a life-threatening allergic reaction (anaphylaxis) occurs before you can obtain a replacement auto injector, use your Allerject device as directed by your healthcare provider, and then seek emergency medical attention. Speak with your healthcare professional if you are concerned about your health or your child’s health. Report any adverse events to Health Canada .